TARS241220P50000
- 2.14
- -3.36-61.09%
Tarsus Pharmaceuticals Newsroom
Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating
Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's Is How to Trade
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Just Reported And Analysts Have Been Lifting Their Price Targets
A Quick Look at Today's Ratings for Tarsus Pharmaceuticals(TARS.US), With a Forecast Between $65 to $84
Disney To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday
Tarsus Pharmaceuticals Is Maintained at Neutral by Goldman Sachs
Tarsus Pharmaceuticals Analyst Ratings
Tarsus Pharmaceuticals Price Target Raised to $65 From $63 at Oppenheimer
Express News | Tarsus Pharmaceuticals Inc : BofA Global Research Raises Price Objective to $68 From $62
Tarsus Pharmaceuticals, Inc. (TARS) Q3 2024 Earnings Call Transcript Summary
Tarsus Pharmaceuticals, Inc. (TARS) Q3 2024 Earnings Call Transcript
Tarsus Pharmaceuticals Gains Some 15% After Hours on Better-Than-Expected Q3 Results
Tarsus Pharmaceuticals Reports Q3 EPS (61c), Consensus (94c)
Tarsus Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Earnings Flash (TARS) TARSUS PHARMACEUTICALS Posts Q3 Revenue $48.1M
Tarsus Pharmaceuticals | 8-K: Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
Express News | Tarsus Pharmaceuticals Q3 Basic EPS USD -0.61
Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
Press Release: Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
Express News | Tarsus Welcomes Kate Goodrich, M.d., Mhs, to Its Board of Directors